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Abstract 
The use of chemotherapy for 
retinoblastoma constitutes a promising 
treatment strategy. Retinoblastoma is the 
most common eye cancer in the childhood.. 
Treatment depends on the laterality, 
intraocular location and tumor extension.  
Radiation therapy became an important 
element in the management of this type of 
injury risk of extraocular secondary tumor 
development. Eye salvage  is  mandatory 
when vision preserved. The current 
neuroendovascular techniques constitute a 
therapeutic tool for these tumors. We 
present a practical review of current 
concepts in the management of these 
tumors.  
Key words: chemosurgery, retino-
blastoma, neurointerventional 
Introduction 
Retinoblastoma (RTB) is a tumor that 
surge from the retinal neuroepithelium, 
and can differentiate into almost any type of 
outer or inner retinal cell, including 
photoreceptors (1). RTB is brought about 
by biallelic inactivation of the human 
retinoblastoma susceptibility gene, RB1 
(GenBank accession number L11910), 
located on chromosome 13q14 that codes 
for the RB protein (2). RTB protein (Rb) 
regulates cell cycle progression and 
suppresses tumorigenesis through the 
control of E2F transcription factor function, 
which in turn represents the link between 
the Rb pathway and the induction of p53-
dependent apoptosis (3–5). RTB arises due 
to two genetic events involving both the 
alleles of RB1 and occurs in two forms, the 
hereditary and non-hereditary. Mutation of 
both the alleles of RB1 is required for 
tumor initiation (2). 
RTB can be unilateral or bilateral with 
sporadic or familial hereditary patterns. 
Patients with unilateral retinoblastoma 
generally carry a somatic mutation in the 
Rb that is present only in the tumor 
without a similar mutation in other cells 
(6). However, almost 10% to 15% of these 
patients manifest a germinal mutation in all 
cells of the body, despite the fact that they 
have unilateral RTB (6). Tables 1 and 2, 
show two classification systems for RTB. 
The aim of this work is to briefly review the 
data regard chemosurgery for RTB 
treatment.
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TABLE 1 
Reese-Ellsworth classification for conservative treatment of retinoblastoma 
Group Consideration Characteristics 
I Very favorable Solitary tumor, <4 disk diameters in size, at or behind the 
equator 
Multiple tumors, none                                                       4 disk 
diameters in size, all at or behind the equator 
II Favorable Solitary tumor, 4–10 disk diameters in size, at or behind the 
equator 
Multiple tumors, 4–10 disk diameters in size, behind the 
equator 
III Doubtful Any lesion anterior to the equator 
Solitary tumors >10 disk diameters behind the equator 
IV Unfavorable Multiple tumors, some >10 disk diameters 
Any lesion extending anteriorly to the ora serrata 
V Very unfavorable Massive tumors involving over half the retina 
Vitreous seeding 
 
TABLE 2 
International retinoblastoma staging system 
Stage Characteristics 
0 Patients treated conservatively 
I Eye enucleated, tumor completely resected on histopathology examination 
II 
Eye enucleated, microscopic residual tumor present in the form of: 
•Tumor invasion into extrascleral tissue 
•Tumor invasion into cut end of optic nerve 
III 
Regional extension: 
•Overt orbital disease 
•Preauricular or cervical lymph node extension 
IV 
Metastatic 
•Hematogenous metastasis (without CNS extension) 
•Single lesion 
•Multiple lesions 
Central nervous system extension (with or without any other site of regional or 
metastatic disease) 
•Prechiasmatic lesion 
•Central nervous sustem mass 
•Leptomeningeal and cerebrospinal fluid (CSF) disease 
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RTB general behaviour 
RTB is the most common malignant 
intraocular tumor of childhood (1,6,7), 
with a reported incidence ranging from 1 in 
15,000 to 1 in 18,000 live births, 
independent of race and sex (8,9); Kivela 
(10) has stated that the estimated number of 
patients per year with RTB worldwide was 
between 7202 and 8102. Approximately 
250–300 children are newly diagnosed with 
retinoblastoma each year in the United 
States, and unfortunately, substantially 
higher rates occur in developing countries 
(11). Almost 80% of the cases occur before 
4 years of age, while 40% of cases occur 
during infancy (1). It is a  curable cancer if 
detected at a stage in which it is still 
contained within the retina, subretinal 
space or vitreous (12). The most common 
external features include leukokoria and 
strabismus (6). Approximately 80%-90% of 
RB1 gene carriers develop ocular tumors. 
This gene encodes the cell cycle regulatory 
retinoblastoma gene protein (pRb), controls 
cellular differentiation during both 
embryogenesis and in adult tissues, 
regulates apoptotic cell death, maintains cell 
cycle arrest and preserves chromosome 
estability [2]. Retinoblastoma occurs in two 
forms: hereditary (30-40%) and non-
hereditary (60-70%). 
Despite the classic appearance of RTB, 
nearly 50% of patients diagnosed initially 
with possible retinoblastoma prove, on 
referral to ocular oncologists, to have 
simulating conditions and not 
retinoblastoma (13). The most common 
pseudoretinoblastomas include persistent 
hyperplastic primary vitreous, Coats 
disease, and ocular toxocariasis (13). 
 
 
Management evolution 
RTB management is complex and 
depends on many issues including tumor 
laterality, macular involvement, tumor size, 
vitreous or subretinal seeding, relationship 
of the tumor to surrounding tissues 
including the optic disc, choroid, iris, sclera, 
and orbit, general patient age and health, 
and the family desires (12). The treatment 
of RTB has evolved substantially over the 
last few decades (12,14,15). Conservative 
treatment of retinoblastoma has improved 
in the last years. In the past, enucleation and 
external beam radiation therapy (EBRT) 
were the only treatments available for these 
patients (7). 
Systemic chemotherapy for intraocular 
retinoblastoma was introduced >50 years 
ago (16). The driving force behind using 
systemic chemotherapy has been to avoid 
the radiation-related second cancers that 
developed in radiated retinoblastoma 
children (16). As had been mentioned, 
patients with RTB are young children and 
although systemic chemotherapy causes 
dramatic reductions in the size of the 
tumors (averaging >50% decrease in 
volume after 3 sessions) clinicians are 
increasingly reporting worrisome adverse 
systemic findings in children treated with 
systemic chemotherapy (16). This therapy 
in the pediatric population has potential 
short- and long-term complications, such as 
neutropenia, fever, port infections, sepsis, 
anemia, transfusions, and associated 
hospitalizations have all been reported (17). 
Since 1997 was previsualized newer 
treatment strategies directed to target cancer 
cell treatment, such as the delivering of a 
photosensitizing agent to cancer cells by a 
carrier molecule such as low-density 
lipoprotein (6,18), posteriorly, a light 
source, e.g., laser, is then used to irradiate 
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the sensitized tumor; allowing for targeted 
treatment with a particularly intense 
reaction in the tumor, sparing the normal 
tissue (6). All management have evolved, 
and currently, the most commonly 
employed approach for treating 
retinoblastoma in developed countries is 
chemoreduction, a strategy involving 
neoadjuvant systemic chemotherapy, 
followed by treatment with focal 
modalities, such as cryotherapy, laser 
treatment, or brachytherapy (19). 
Laser photocoagulation, cryotherapy, 
thermotherapy, and plaque radiotherapy 
remain vitally important in the 
management of selective RTB (12). 
Enucleation, intravenous chemoreduction, 
intra-arterial chemotherapy, and EBRT are 
used for more advanced retinoblastoma 
(12). EBRT is usually reserved for last 
alternative treatment because of its 
numerous side effects and risks for late 
onset cancers in germline mutation 
children (12). 
Chemosurgery 
Ophthalmic artery chemosurgery 
(OAC) for RTB was first performed a 
lustrum ago by Abramson et al (20,21) with 
the aim of preserv eyes with extensive 
intraocular RTB scheduled for enucleation.  
The first attempt to deliver high doses to 
the eye, while minimizing systemic 
exposure was performed by Reese et al (22) 
more than 50 years ago, but with a different 
rationale; they delivered intra-arterial 
Triethylene Melanamine (TEM) (a 
nitrogen mustard derivative) via direct 
carotid artery puncture on the side to be 
treated attempting to lower the dose of 
therapeutic radiation used to treat RTB.  
Japanese researchers have been 
investigated intracarotid administration of 
chemotherapy. Intra-arterial chemotherapy 
was used in 187 patients in Japan between 
1988 and 2001 (23,24). Initially, they 
described only technical success, without 
efficacy or toxicity data. Some follow-up 
data were reported in October, 2011 (25). 
Ophthalmic arterial infusion of melphalan 
is technically feasible and can result in 
striking regression of tumour 
(16,21,26).79–81 These optimistic reports 
do not specify eligibility criteria, control of 
retinoblastoma, vision achieved, or survival 
rates of the eye or patient. However, in 
their studies, many patients received 
external beam radiotherapy (EBRT) and 
intravitreal melphalan, making it difficult to 
determine how effective the intraarterial 
injections would be if used alone (11). 
Abramson et al in 2010 (16) introduced 
the technique of “super selective infusion” 
by advancing a micro-catheter into the 
orifice of the ophthalmic artery on the side 
to be treated (or both sides in the same 
session in cases of bilateral retinoblastoma- 
‘‘tandem therapy’’) after introduction of the 
catheter via the femoral artery in cases of 
newly diagnosed retinoblastomas. Because 
of their limited systemic toxicity in treating 
children with advanced intraocular 
retinoblastoma (most frequently 
asymptomatic Grade 3 neutropenia), they 
began treating less advanced retinoblastoma 
and in 2012 they report the success and 
adverse events in these patients (20); they 
found that ophthalmic artery chemosurgery 
for retinoblastoma that was Reese-
Ellsworth I, II and III (or International 
Classification B or C) was associated with 
high success (100% of treatable eyes were 
retained) and limited toxicity with results 
that equal or exceed conventional therapy 
with less toxicity. Thus, this technique, 
rapidly become an accepted modality that 
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saves eyes with advanced RTB that would 
otherwise have been enucleated. 
The evidence showed that many of the 
eyes initially managed with systemic 
chemotherapy require additional 
treatment(s) (radiation or enucleation) to 
control the cancer (16), making 
chemosurgery an option of particular 
interest, because it could be performed 
repeatedly in young children without 
significant systemic or local side effects 
(16); furthermore, in some  cases, eyes 
clearly can have potential useful vision (16).  
Because the most newly diagnosed RTB 
eyes in the United States are in Reese-
Ellsworth group V at presentation (16), the 
majority of these are treated with primary 
enucleation; however in the Abramson (16) 
series, 25 of 28 were classified as Reese-
Ellsworth group V. They would likely have 
been primarily enucleated, but the intra-
arterial approach allowed them to save 27 of 
these eyes. 
Abramson et al (16) 3-year experience 
with the use of super selective intra-arterial 
chemotherapy for RTB suggests that the 
technique is minimally toxic to the eye in 
previously untreated cases, has minimal 
systemic toxicity, can restore vision in some 
eyes, can be done repeatedly on an 
outpatient basis, and will replace the use of 
systemic chemotherapy, EBRT, and 
enucleation for the majority of 
retinoblastoma cases. Other reports also 
support those findings (27) 
The technique 
Chemosurgery is a method of intra-
arterial chemotherapy is basically a 
procedure in which a neuro-interventional 
radiologist or neurosurgeon will thread a 
catheter into femoral approach, reaching 
ophthalmic artery and releasing the 
medications (14). For the super selective 
technique described by Abramson et al (16), 
under general anesthesia and 
anticoagulation (intravenous heparin, 75I 
U/kg), is introduced into the femoral artery 
a 4-French arterial sheath. Microcatheters 
are then passed into the ophthalmic artery 
on the affected side using fluoroscopy and 
roadmapping (16). Both flow-directed 
catheters (such as the Magic-Balt 
Therapeutics, Montmorency, France) with 
outer diameters of 400 or 500 microns and 
guidewire-directed catheters (such as the 
Excelsior SL 10 Stryker, Freemont CA) 
with an outer diameter of 570 microns have 
been used. The chemotherapy drugs are 
then diluted with saline in a 30cc solution, 
injected in a pulsatile fashion over 30 
minutes. At the end of the procedure the 
catheter is withdrawn, the femoral puncture 
site is compressed for hemostasis and the 
child discharged the same day (16). 
Despite its remarkable control for 
retinoblastoma, some authors consider that 
intraarterial chemotherapy should be used 
with caution (14). Have been demonstrated 
some toxic effects of irradiation from 
fluoroscopy during intraarterial 
chemotherapy for retinoblastoma, 
cautioning that accumulated irradiation 
toxic effects following multiple sessions of 
intraarterial chemotherapy could be 
cataractogenic and possibly carcinogenic 
(28). 
Survival and outcomes 
Survival rates for intraocular RTB have 
improved dramatically in the past century. 
A disease that was 95% lethal 100 years ago 
is now curable in more than 95% of cases 
(19); Its management relies on an 
experienced team, conformed by the ocular 
oncologists, pediatric oncologists, radiation 
oncologists, pediatricians, pediatric 
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ophthalmologists, geneticists, and 
occasionally interventional 
neuroradiologists or neurosurgeons 
working together for the single goal of 
saving the child’s life (12). 
In America, the 5-year survival was 96% 
between 1995 and 2004 based on 
Surveillance, Epidemiology, and End 
Results (SEER) data (29). In England, the 
5-year survival between 1998 and 2002 was 
97% for unilateral retinoblastoma and 100% 
for bilateral retinoblastoma (30). 
Despite these impressive results, 
retinoblastoma continues to pose a serious 
life-threatening problem for children in 
developing nations, mostly due to late 
detection and massive tumor. The mortality 
rate varied tremendously by location with 
3–5% mortality in Japan, Europe, and 
North America to 20% in Latin 
America/Caribbean, 39% in Asia (without 
Japan), and up to 70% in Africa. He 
estimated that approximately 3001–3376 
children die of retinoblastoma annually 
worldwide (10).  
Conclusions 
Early detection to minimize visual 
morbidity remains the focus of research in 
countries with universal access to 
healthcare. Late presentation with life 
threatening disease is a major challenge in 
economically underprivileged countries, 
and strategies must focus on raising 
awareness and acceptance of modern 
treatment methods such as chemosurgery. 
Fortunately the strategies for treating RTB 
continue evolving, some successfully, and 
others no. Despite advances in treatment 
options, clinicians continue to face 
challenges in improving globe salvage rates 
and mitigating the long-term side effects of 
therapy. 
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